Table 6.
Effects of the bound peptide on the interaction of KIR with HLA-C.
| KIR | HLA class I | Assay | Results | Reference |
|---|---|---|---|---|
| 2DL2/3 | C*03:04/multiple peptides | Inhibition of NK cell-mediated killing of RMA-S cells with transfected HLA class I | GAVDPLLAL or TAMDVVYAL presented on C*03:04 protect from lysis; alternative peptides showed weaker inhibition | Zappacosta et al. (1997) |
| 2DL2 and 2DL3 | C*01:02/VAPWNSLSL | Binding of KIR-Fc and inhibition of NK cell degranulation against RMA-S cells with transfected HLA class I | Screened 58 p7/p8 variants; weak versus strong (>2-fold) binding observed; binding correlated with NK activity | Fadda et al. (2010) |
| 2DL1 | C*04:01/QYDDAVYKL | Binding of KIR-Fc and inhibition of NK cell clone killing against RMA-S cells with transfected HLA class I | Substitutions at p7 and p8 (Y7E, K8E, and K8D) abrogate binding of 2DL1 to C*04:01, despite stabilizing cell-surface HLA-C | Rajagopalan and Long (1997) |
| 2DL2 | C*03:04/GAVDPLLAL | Biacore analysis | Mutation of p8 (A to Y or K) abrogates 2DL2 binding, despite stabilizing pHLA expression | Boyington et al. (2000) |
| 2DL1, 2DL2, 2DL3, 2DS1, and 2DS2 | C*04:01/QYDDAVYKL and C*03:04/GAVDPLLAL and peptide mutants | Biacore analysis | Alteration of p8 disrupts KIR/HLA binding (10X or greater); p7 contributes to affinity | Stewart et al. (2005) |